Author

Tina T. Som

Observed names: Tina Som, Tina T Som

Institution: Massachusetts General Hospital

Observed institutions: Harvard University, Massachusetts General Hospital

OpenAlex ID: A5081484812

PD-1 inhibition in advanced myeloproliferative neoplasms

2021 · Gabriela Hobbs, Cansu Cimen Bozkus, et al. · Blood Advances · 46

Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia

2020 · Monica Kasbekar, Valentina Nardi, et al. · Blood Advances · 45

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia

2016 · Amir T. Fathi, Seth A. Wander, et al. · Haematologica · 41

PDF

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation

2017 · Amir T. Fathi, Traci M. Blonquist, et al. · Cancer · 31

PDF

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial

2019 · Andrew M Brunner, Traci M Blonquist, et al. · The Lancet Haematology · 30

PDF

A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia

2019 · Rupa Narayan, Traci M. Blonquist, et al. · Cancer · 27

PDF

Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia

2018 · Andrew M. Brunner, Traci M. Blonquist, et al. · Blood · 10

Results of a Phase II Study of PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

2020 · Gabriela S. Hobbs, Cansu Cimen Bozkus, et al. · Blood · 7

Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults

2022 · Philip Amrein, Karen Ballen, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 4

A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia

2016 · Amir T. Fathi, Traci M. Blonquist, et al. · Blood · 4

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies

2022 · Joan How, Siyang Ren, et al. · eJHaem · 2

PDF

Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults

2020 · Philip C. Amrein, Karen K. Ballen, et al. · Blood · 1

Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults

2025 · Philip C. Amrein, Frederic I. Preffer, et al. · Leukemia & lymphoma/Leukemia and lymphoma

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

2022 · Philip C. Amrein, Eyal C. Attar, et al. · Blood

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

2020 · Philip C. Amrein, Eyal C. Attar, et al. · Blood

A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies

2020 · Chi-Joan How, Siyang Ren, et al. · Blood

Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program

2019 · Monica Kasbekar, Valentina Nardi, et al. · Blood

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults

2018 · Philip C. Amrein, Eyal C. Attar, et al. · Blood

Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia

2018 · Amir T. Fathi, Traci M. Blonquist, et al. · Blood

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

2018 · Philip C. Amrein, Karen K. Ballen, et al. · Blood

Works count: 20

Citation count: 248

H-index: 7

I10-index: 7